NVO
| Market cap | $293.86B |
|---|---|
| Enterprise value | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| Income | kr52.825B |
| Revenue Q/Q | 27.92% |
| Revenue Y/Y | 24.21% |
| P/E | 57.47 |
|---|---|
| Forward P/E | N/A |
| EV/Sales | 1.58 |
| EV/EBITDA | N/A |
| EV/EBIT | 12.82 |
| PEG | 1.79 |
| Price/Sales | 12.84 |
| P/FCF | 4.94 |
| Price/Book | 24.96 |
| Book/Share | 5.64 |
| Cash/Share | N/A |
| FCF yield | 2.77% |
| Volume | 2.636M / 3.591M |
|---|---|
| Relative vol. | 0.73 × |
| EPS | 2.45 |
|---|---|
| EPS Q/Q | -4.88% |
| Est. EPS Q/Q | 6.17% |
| Profit margin | N/A |
|---|---|
| Oper. margin | 43.10% |
| Gross margin | N/A |
| EBIT margin | 43.10% |
| EBITDA margin | 6.80% |
| Ret. on assets | 24.76% |
|---|---|
| Ret. on equity | 73.26% |
| ROIC | 28.26% |
| ROCE | 64.00% |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.92 |
| Quick ratio | 0.74 |
| Volatility | 1.73% |
|---|---|
| Beta | 0.60 |
| RSI | 60.31 |
|---|
| Insider ownership | 0.00% |
|---|---|
| Inst. ownership | 8.30% |
| Shares outst. | 3.390B |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 0.00% |
| Short ratio | 2.67 |
| Dividend | $1.81 |
|---|---|
| Dividend yield | 1.29% |
| Payout ratio | 74.02% |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | 7 Aug 2024 |
Tuesday, 18 June 2024
|
|
| Blaze at Danish drugmaker Novo Nordisk is the third in a little over a month | |
Friday, 14 June 2024
|
|
| Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy | |
Wednesday, 12 June 2024
|
|
| ASML, Novo Nordisk, Spotify Boast This Sign Of Stock Market Leadership | |
| Bernie Sanders Wants to Subpoena Novo Nordisk Over Wegovy’s Price. What to Know. | |
Wednesday, 5 June 2024
|
|
| Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | |
| Netflix, Novo Nordisk Join 3 Fashionable Breakouts; 4 IPOs In Focus | |
Tuesday, 28 May 2024
|
|
| Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System | |
Monday, 27 May 2024
|
|
| The Biggest Biotechnology Company in Europe | |
Tuesday, 21 May 2024
|
|
| Eli Lilly's diabetes drug tirzepatide gets approval in China | |
Monday, 20 May 2024
|
|
| Hims & Hers Stock Spikes. It’s Taking on Big Pharma With Cheap Obesity Shots. | |
Saturday, 18 May 2024
|
|
| Microsoft Leads Five Stocks Near Buy Points As Market Flashes Green | |
Wednesday, 15 May 2024
|
|
| Novo Nordisk Weigh-Loss Drugs Could Bankrupt US Health Care, Senate Committee Report Says | |
| No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms | |
| Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound | |
Monday, 13 May 2024
|
|
| Wegovy weight loss sustained for four years in trial, Novo Nordisk says | |
Thursday, 9 May 2024
|
|
| Novo Nordisk Sets Sights on a Long-Lasting Successor to Its Weight Loss Blockbuster | |
Tuesday, 7 May 2024
|
|
| 13 Best Stocks That Will Always Grow | |
Friday, 3 May 2024
|
|
| UPDATE 1-US FTC seeks more information on Novo Nordisk parent-Catalent deal | |
| Novo Slides as Amgen Fuels Obesity Drug Competition Fears | |
| Here’s How Novo Holdings’ Catalent Acquisition Affects Laughing Water Capital | |
Powered by
Robintrack.
Price target
Current $135.28
Average $11.53
Low $8
High $14
Dividends
| Ex-dividend date | N/A | Frequency | Irregular | Annual dividend | +27.95% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 1.29% | Growth period | 3 years |
| Last dividend date | Yield 3 years | 1.50% | Growth 3 years | +16.67% | |
| Last dividend | Yield 5 years | 1.54% | Growth 5 years | +12.76% |
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Lars Fruergaard Jorgensen (55) Pres, CEO, and Member of Management Board | 55 | $5,424,793 | |
| Henrik Ehlers Wulff (51) Exec. VP, Head of Product Supply, Quality, IT, and Member of the Management Board | 51 | $2,112,174 | |
| Camilla Sylvest (49) Exec. VP, Head of Commercial Strategy, Corp. Affairs, and Member of the Management Board | 49 | $2,005,806 | |
| Karsten Munk Knudsen (50) Exec. VP, CFO, and Member of the Management Board | 50 | $2,005,806 | |
| Monique Carter (48) Exec. VP, Head of People, Organisation, and Member of Management Board | 48 | $1,519,550 | |
| Marcus Schindler Ph.D. (55) Exec. VP of Research, Early Devel., CSO, and Member of the Management Board | 55 | ||
| Martin Holst Lange | |||
| Ludovic Helfgott (47) Exec. VP, Head of Biopharm, and Member of Management Board | 47 | ||
| Douglas J. Langa (55) Exec. VP, Head of North America Operations, and Member of Management Board | 55 | ||
| Maziar Mike Doustdar (51) Exec. VP, Head of International Operations, and Member of the Management Board | 51 |
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries.
- Health Care > Biotechnology
- Novo Nordisk, Novo Allé 1, Bagsvaerd 2880, Denmark
- 45 44 44 88 88
- Investor relations
Dividends
| Ex-dividend date | N/A | Frequency | Irregular | Annual dividend | +27.95% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 1.29% | Growth period | 3 years |
| Last dividend date | Yield 3 years | 1.50% | Growth 3 years | +16.67% | |
| Last dividend | Yield 5 years | 1.54% | Growth 5 years | +12.76% |
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions DKK) | 29 Sep 2022 | 29 Jun 2022 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | kr28,465 | kr22,758 | |||
| Short term investments | kr9,008 | kr8,279 | |||
| Net receivables | kr53,510 | kr46,639 | |||
| Inventory | kr23,222 | kr21,706 | |||
| Other current assets | kr5,277 | kr3,597 | |||
| Total current assets | kr119,482 | kr102,979 | |||
| Long term investments | kr1,239 | kr1,242 | |||
| Property, plant & equipment | kr63,641 | kr59,556 | |||
| Goodwill | |||||
| Intangible assets | kr46,924 | kr44,590 | |||
| Other assets | kr11,550 | kr10,561 | |||
| Total assets | kr242,836 | kr218,928 | |||
| Current liabilities | |||||
| Accounts payable | kr8,310 | kr14,654 | |||
| Short long term debt | |||||
| Other current liabilities | kr120,114 | kr93,745 | |||
| Total current liabilities | kr130,257 | kr109,655 | |||
| Long term debt | kr24,136 | kr24,178 | |||
| Other liabilities | kr11,763 | kr10,643 | |||
| Minority interest | |||||
| Total liabilities | kr166,156 | kr144,476 | |||
| Stockholders' equity | |||||
| Common stock | kr456 | kr456 | |||
| Retained earnings | kr73,673 | kr73,166 | |||
| Treasury stock | kr2,551 | kr830 | |||
| Capital surplus | |||||
| Total stockholder equity | kr76,680 | kr74,452 | |||
| Net tangible assets | kr29,756 | kr29,862 | |||
| (in millions DKK) | 2021 | 2020 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | kr10,720 | kr12,757 | ||
| Short term investments | kr6,765 | |||
| Net receivables | kr46,799 | kr32,184 | ||
| Inventory | kr19,621 | kr18,536 | ||
| Other current assets | kr1,690 | kr2,332 | ||
| Total current assets | kr85,595 | kr65,809 | ||
| Long term investments | kr1,441 | kr1,648 | ||
| Property, plant & equipment | kr55,362 | kr50,269 | ||
| Goodwill | kr4,346 | |||
| Intangible assets | kr38,825 | kr20,657 | ||
| Other assets | kr8,939 | kr6,539 | ||
| Total assets | kr194,508 | kr144,922 | ||
| Current liabilities | ||||
| Accounts payable | kr8,870 | kr5,717 | ||
| Short long term debt | ||||
| Other current liabilities | kr26,395 | kr57,097 | ||
| Total current liabilities | kr99,516 | kr70,273 | ||
| Long term debt | kr9,654 | |||
| Other liabilities | kr11,285 | kr8,427 | ||
| Minority interest | ||||
| Total liabilities | kr123,762 | kr81,597 | ||
| Stockholders' equity | ||||
| Common stock | kr462 | kr470 | ||
| Retained earnings | kr72,004 | kr63,774 | ||
| Treasury stock | -kr1,720 | -kr919 | ||
| Capital surplus | ||||
| Total stockholder equity | kr70,746 | kr63,325 | ||
| Net tangible assets | kr27,575 | kr42,668 | ||
Income statement
| (in millions DKK) | 29 Sep 2022 | 29 Jun 2022 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | kr45,566 | kr41,265 | |||
| Cost of revenue | kr7,200 | kr6,069 | |||
| Gross profit | kr38,366 | kr35,196 | |||
| Operating activities | |||||
| Research & development | kr5,633 | kr5,123 | |||
| Selling, general & administrative | kr12,609 | kr11,831 | |||
| Total operating expenses | kr25,382 | kr22,874 | |||
| Operating income | kr20,184 | kr18,391 | |||
| Income from continuing operations | |||||
| Net other income | -kr2,152 | -kr1,596 | |||
| EBIT | kr20,184 | kr18,391 | |||
| Income before tax | kr18,032 | kr16,795 | |||
| Income tax expense | kr3,627 | kr3,477 | |||
| Minority interest | |||||
| Net income | |||||
| Net income | kr14,405 | kr13,318 | |||
| Income (for common shares) | kr14,405 | kr13,318 | |||
| (in millions DKK) | 2021 | 2020 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | kr140,800 | kr126,946 | ||
| Cost of revenue | kr23,658 | kr20,932 | ||
| Gross profit | kr117,142 | kr106,014 | ||
| Operating activities | ||||
| Research & development | kr17,199 | kr15,112 | ||
| Selling, general & administrative | kr41,058 | kr36,886 | ||
| Total operating expenses | kr81,459 | kr72,470 | ||
| Operating income | kr59,341 | kr54,476 | ||
| Income from continuing operations | ||||
| Net other income | -kr261 | -kr1,346 | ||
| EBIT | kr59,341 | kr54,476 | ||
| Income before tax | kr59,080 | kr53,130 | ||
| Income tax expense | kr11,323 | kr10,992 | ||
| Minority interest | ||||
| Net income | ||||
| Net income | kr47,757 | kr42,138 | ||
| Income (for common shares) | kr47,757 | kr42,138 | ||
Cash flows
| (in millions DKK) | 29 Sep 2022 | 29 Jun 2022 | |||
|---|---|---|---|---|---|
| Net income | kr14,405 | kr13,318 | |||
| Operating activities | |||||
| Depreciation | kr2,041 | kr1,636 | |||
| Change in accounts receivable | |||||
| Changes in inventory | |||||
| Total cash flows from operations | kr24,239 | kr23,961 | |||
| Investing activities | |||||
| Capital expenditures | -kr3,230 | -kr2,435 | |||
| Investments | -kr736 | -kr1,625 | |||
| Other cash flows from investing | |||||
| Total cash flows from investing | -kr4,961 | -kr4,200 | |||
| Financing activities | |||||
| Dividends paid | -kr9,613 | ||||
| Net borrowings | -kr330 | -kr244 | |||
| Other cash flows from financing | -kr2,737 | ||||
| Total cash flows from financing | -kr14,563 | -kr10,431 | |||
| Effect of exchange rate | kr443 | kr218 | |||
| Change in cash and equivalents | kr5,158 | kr9,548 | |||
| (in millions DKK) | 2021 | 2020 | ||
|---|---|---|---|---|
| Net income | kr47,757 | kr42,138 | ||
| Operating activities | ||||
| Depreciation | kr5,111 | kr5,069 | ||
| Change in accounts receivable | -kr12,909 | -kr2,822 | ||
| Changes in inventory | -kr1,085 | -kr895 | ||
| Total cash flows from operations | kr55,000 | kr51,951 | ||
| Investing activities | ||||
| Capital expenditures | -kr6,335 | -kr5,825 | ||
| Investments | -kr5,941 | -kr380 | ||
| Other cash flows from investing | kr4 | kr18 | ||
| Total cash flows from investing | -kr31,605 | -kr22,436 | ||
| Financing activities | ||||
| Dividends paid | -kr21,517 | -kr20,121 | ||
| Net borrowings | kr15,471 | kr4,732 | ||
| Other cash flows from financing | ||||
| Total cash flows from financing | -kr25,493 | -kr32,244 | ||
| Effect of exchange rate | kr591 | -kr456 | ||
| Change in cash and equivalents | -kr1,507 | -kr3,185 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q1 | Natixis Advisors, L.P. |
-1.91%
|
2,993,960 | $384,424 |
| 2024 Q1 | Cambridge Investment Research Advisors |
+18.50%
|
197,214 | $25,322 |
| 2024 Q1 | Integrated Wealth Concepts |
+34.64%
|
33,307 | $4,276,646 |
| 2024 Q1 | Penobscot Investment Management |
+20.47%
|
38,759 | $4,976,656 |
| 2024 Q1 | Eads & Heald Wealth Management |
Opened
|
2,623 | $337 |
| 2024 Q1 | Zhang |
Opened
|
2,480 | $318,432 |
| 2024 Q1 | Keystone |
Opened
|
2,393 | $307,262 |
| 2024 Q1 | Kanawha Capital Management |
Opened
|
2,148 | $275,803 |
| 2024 Q1 | Vestor Capital |
Opened
|
1,924 | $247 |
| 2024 Q1 | Eukles Asset Management |
-2.86%
|
54,333 | $6,976,418 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Natixis Advisors, L.P. | 0.09% | 2,993,960 | |
| Cambridge Investment Research Advisors | 0.01% | 197,214 | |
| Lenox Wealth Management | 0.00% | 95,621 | |
| Eukles Asset Management | 0.00% | 54,333 | |
| Penobscot Investment Management | 0.00% | 38,759 | |
| North Star Asset Management Inc | 0.00% | 35,143 | |
| Integrated Wealth Concepts | 0.00% | 33,307 | |
| Highlander Capital Management | 0.00% | 25,100 | |
| Baldwin Investment Management | 0.00% | 22,641 | |
| Cpwm | 0.00% | 18,411 |
Sign up